CHANGEBLOCK
27.11.2023 11:32:27 CET | Business Wire | Press release
Changeblock, a global sustainability fintech company utilizing advanced data-systems and technologies to accelerate planet repair and protection activities through the generation and exchange trading of high-integrity environmental assets, such as carbon credits, today announced the appointment of Baroness Evans of Bowes Park, former leader of the UK House of Lords, as Senior Advisor, Policy & Ethics.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231123431705/en/
Baroness Natalie Evans of Bowes Park, former UK Cabinet Minister as Leader of the House of Lords and Senior Advisor, Policy and Ethics of Changeblock Limited. (Photo: Business Wire)
Trust and integrity are crucial for companies to monetize their planet repair and protect initiatives, and therefore crucial for credits to be adopted at the scale necessary towards achieving net-zero, Consequently, policy and ethics are major focus areas for Changeblock that require integration into the credit value chain. The appointment of Baroness Evans will significantly strengthen the Company’s efforts in this regard, and augments the work already being done with multiple standard and verification agencies.
Baroness Evans commented, “Reducing society’s environmental footprint is one of the most pressing challenges we as humanity are facing today, and tradeable offsets, such as credits, hold great promise towards delivering this. Their effectiveness will be impacted by how the companies in this eco-system engage with policy and policy makers.
“Ethics play an increasingly important role in credit integrity assessments and in investment decision making. Changeblock’s forward, strategic thinking, combined with their unique offering that meets such a critical need, make this an exciting opportunity. I look forward to working with Billy and the team and help Changeblock cement its leadership position as a critical net-zero infrastructure partner.”
Billy Richards, Changeblock CEO, stated, “We believe Baroness Evans is exceptionally well positioned to provide Changeblock with actionable insights, and help us strengthen our position as a critical infrastructure partner for credit generators, off-setters, investors and policy makers. I believe this appointment reflects the importance, integrity and quality of our offering, as well as the depth and strength of our network, and I am excited to be working on these important initiatives with Natalie as we expand our operations and help smooth the path to net-zero.”
Baroness Evans
Baroness Evans of Bowes Park is a Conservative member of the House of Lords. She was appointed a life peer in October 2014, and acted as Leader of the House of Lords and a member of the UK Government’s Cabinet from 2016 to 2022 - the longest serving Leader for 70 years. Between 2015 and 2016 she was a junior Government minister in the Department of Education, Department for Work and Pensions, and the Ministry of Justice. Before entering the Lords, Natalie held a variety of senior positions including CEO of the New Schools Network, Deputy Director of Policy Exchange, and Head of Policy at the British Chambers of Commerce.
Changeblock at COP28
Billy Richards and Baroness Natalie Evans from Changeblock will attend COP28 in Dubai. Changeblock is hosting a roundtable with leaders like David Greenall (KPMG), Jim Andrew (Pepsico), and Michael Terrell (Google), discussing AI analytics in carbon offsetting. The roundtable, titled “The Critical Role of Integrity in Carbon Credits and Offsets for Effective Planet Repair,” will explore sustainable carbon mitigation strategies.
About Changeblock
Changeblock creates global markets that make the creation and trade of environmental assets for individuals, businesses, and governments easy, affordable, transparent, secure, and environmentally responsible. The company is led by professionals with deep expertise in technology and environmental credits with a proven track record in building and delivering solutions that work in the real world, including members of the team that created the first carbon credit, and come from top global organisations.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231123431705/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Merz Therapeutics Presents New Phase 2 PaiNT Data in Peripheral Neuropathic Pain at IASP 202626.10.2026 08:00:00 CET | Press release
Clinical and preclinical presentations reflect the company’s ongoing exploration of peripheral neuropathic pain Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced the presentation of new clinical and translational research in peripheral neuropathic pain (PNP) at the International Association for the Study of Pain (IASP) 2026 World Congress in Bangkok, Thailand, taking place from 26 to 30 October. The research spans new Phase 2 findings on incobotulinumtoxinA in postherpetic neuralgia (PHN) and post-surgical/post-traumatic neuropathic pain (PS/PTNP), as well as preclinical studies exploring potential biological mechanisms involved in effects of incobotulinumtoxinA on PNP models, highlighting Merz Therapeutics’ growing presence in neuropathic pain. In the PHN population of the Phase 2 PaiNT trial, results over 20 weeks favored incobotulinumtoxinA versus placebo treatment. In an exploratory analysis of average daily pain (ADP) intensity, the greates
Andersen Consulting tilføjer samarbejdsfirmaet TechSparq25.10.2026 06:09:00 CET | Pressemeddelelse
Andersen Consulting udvider sine kompetencer inden for teknologi og forretningstransformation gennem en samarbejdsaftale med TechSparq, en amerikansk virksomhed, der kombinerer strategi, commerce engineering og ai med praktisk implementering. TechSparq er et digitalt konsulenthus, der tilbyder strategi- og rådgivningstjenester, commerce engineering samt tjenester inden for ai og agentbaseret handel til virksomheder inden for detailhandel og forbrugsgoder, luksus og mode samt e-handel og direkte salg til forbrugere. Virksomheden har hovedkontor i Oregon og kombinerer strategisk planlægning med praktisk implementering for at hjælpe kunderne med at udvikle deres digitale initiativer, kundeoplevelse og driftsmodeller. "Vi etablerede vores virksomhed for at bygge bro mellem dem, der udvikler strategien, og dem, der har ansvaret for at føre den ud i livet," udtalte Dedrick Boyd, stifter af og administrerende direktør for TechSparq. "Vores samarbejde med Andersen Consulting giver os mulighed
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press release
Potential first-in-class GPC3 x 4-1BB bispecific achieves a 36% confirmed response rate at Phase 3 dose and favorable safety profile in heavily pretreated liver cancerBrain-penetrant PRMT5 inhibitor shows promising antitumor and CNS activity in the largest publicly shared MTAP-deficient datasetFirst clinical data of CEA-targeting ADC demonstrates encouraging and sustained responses in CEAhigh NSCLC BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to dise
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom